David Pernock Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for David Pernock.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of David Pernock. David Pernock is Chairman and CEO in Fibrocell Science, Inc. ($FCSC) and Chief Executive Officer in Fibrocell Science, Inc. ($FCSC) and Director in Fibrocell Science, Inc. ($FCSC) and Director in EAGLE PHARMACEUTICALS, INC. ($EGRX) and Pres & Chief Operating Officer in EAGLE PHARMACEUTICALS, INC. ($EGRX) and Pres. & Chief Comm. Officer in EAGLE PHARMACEUTICALS, INC. ($EGRX).
Latest Insider Trading Transactions of David Pernock
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 04 2021 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres & Chief Operat ... | Grant | A | 0.00 | 9,700 | 0 | 54,625 | 44.9 K to 54.6 K (+21.59 %) |
Jan 26 2021 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres & Chief Operat ... | Payment of Exercise | F | 47.70 | 1,892 | 90,248 | 44,925 | 46.8 K to 44.9 K (-4.04 %) |
Jan 11 2021 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres & Chief Operat ... | Payment of Exercise | F | 50.97 | 906 | 46,179 | 46,817 | 47.7 K to 46.8 K (-1.90 %) |
Jan 07 2021 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres & Chief Operat ... | Payment of Exercise | F | 50.02 | 2,088 | 104,442 | 47,723 | 49.8 K to 47.7 K (-4.19 %) |
Jan 27 2020 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Payment of Exercise | F | 57.98 | 1,793 | 103,958 | 49,811 | 51.6 K to 49.8 K (-3.47 %) |
Jan 07 2020 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Option Exercise | A | 59.80 | 51,000 | 3,049,545 | 51,000 | |
Jan 07 2020 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Payment of Exercise | F | 57.38 | 904 | 51,872 | 51,604 | 52.5 K to 51.6 K (-1.72 %) |
Jan 07 2020 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Grant | A | 0.00 | 21,500 | 0 | 52,508 | 31 K to 52.5 K (+69.34 %) |
Jan 25 2019 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Option Exercise | A | 42.40 | 46,600 | 1,975,840 | 46,600 | |
Jan 25 2019 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Grant | A | 0.00 | 20,900 | 0 | 31,008 | 10.1 K to 31 K (+206.77 %) |
Jan 25 2019 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Payment of Exercise | F | 41.33 | 858 | 35,461 | 10,108 | 11 K to 10.1 K (-7.82 %) |
Jan 09 2018 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Option Exercise | A | 0.00 | 30,000 | 0 | 30,000 | |
Jan 09 2018 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Option Exercise | A | 59.14 | 50,000 | 2,957,000 | 50,000 | |
Jan 09 2018 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Grant | A | 0.00 | 10,000 | 0 | 10,966 | 966 to 11 K (+1,035.20 %) |
May 19 2017 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Buy | P | 79.69 | 255 | 20,321 | 966 | 711 to 966 (+35.86 %) |
May 16 2017 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Buy | P | 82.24 | 200 | 16,448 | 711 | 511 to 711 (+39.14 %) |
Mar 21 2017 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Buy | P | 83.98 | 61 | 5,123 | 511 | 450 to 511 (+13.56 %) |
Mar 10 2017 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Buy | P | 77.84 | 450 | 35,028 | 450 | 0 to 450 |
Jan 06 2017 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Option Exercise | A | 84.92 | 90,000 | 7,642,800 | 90,000 | |
Dec 02 2016 | FCSC | Fibrocell Science, ... | Pernock David | Chairman and CEO | Buy | P | 0.92 | 50,000 | 46,085 | 105,600 | 55.6 K to 105.6 K (+89.93 %) |
Mar 02 2016 | FCSC | Fibrocell Science, ... | Pernock David | Chairman and CEO | Option Exercise | A | 2.27 | 425,000 | 964,750 | 425,000 | |
Jan 05 2016 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Director | Option Exercise | A | 86.15 | 15,000 | 1,292,250 | 15,000 | |
Nov 13 2015 | FCSC | Fibrocell Science, ... | Pernock David | Chairman and CEO | Buy | P | 5.00 | 3,000 | 14,997 | 55,600 | 52.6 K to 55.6 K (+5.70 %) |
Aug 11 2015 | FCSC | Fibrocell Science, ... | Pernock David | Chairman and CEO | Buy | P | 6.54 | 3,500 | 22,890 | 52,600 | 49.1 K to 52.6 K (+7.13 %) |
May 13 2015 | FCSC | Fibrocell Science, ... | Pernock David | Chairman and CEO | Buy | P | 4.30 | 15,000 | 64,485 | 49,100 | 34.1 K to 49.1 K (+43.99 %) |
May 13 2015 | FCSC | Fibrocell Science, ... | Pernock David | Chairman and CEO | Buy | P | 4.29 | 1,600 | 6,862 | 34,100 | 32.5 K to 34.1 K (+4.92 %) |
Apr 22 2015 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Director | Option Exercise | A | 59.31 | 15,000 | 889,650 | 15,000 | |
Apr 10 2015 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Director | Option Exercise | A | 46.81 | 10,000 | 468,100 | 10,000 | |
Apr 10 2015 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Director | Option Exercise | A | 46.81 | 10,000 | 468,100 | 10,000 | |
Dec 15 2014 | FCSC | Fibrocell Science, ... | Pernock David | Chairman and CEO | Buy | P | 2.52 | 5,000 | 12,600 | 32,500 | 27.5 K to 32.5 K (+18.18 %) |
Nov 21 2014 | FCSC | Fibrocell Science, ... | Pernock David | Chairman and CEO | Buy | P | 2.54 | 5,000 | 12,686 | 27,500 | 22.5 K to 27.5 K (+22.22 %) |
Jun 06 2014 | FCSC | Fibrocell Science, ... | Pernock David | Chief Executive Off ... | Buy | P | 2.95 | 12,500 | 36,925 | 22,500 | 10 K to 22.5 K (+125.00 %) |
Nov 21 2013 | FCSC | Fibrocell Science, ... | Pernock David | Chief Executive Off ... | Buy | P | 3.69 | 10,000 | 36,900 | 10,000 | 0 to 10 K |
Nov 18 2013 | FCSC | Fibrocell Science, ... | Pernock David | Chief Executive Off ... | Option Exercise | A | 3.40 | 800,000 | 2,720,000 | 1,203,000 | |
Jul 23 2013 | FCSC | Fibrocell Science, ... | Pernock David | Chief Executive Off ... | Option Exercise | A | 5.49 | 175,000 | 960,750 | 403,000 | |
Apr 12 2011 | FCSC | Fibrocell Science, ... | Pernock David | Chief Executive Off ... | Option Exercise | A | 0.82 | 1,500,000 | 1,230,000 | 5,700,000 | |
Jan 18 2011 | FCSC | Fibrocell Science, ... | Pernock David | Chief Executive Off ... | Option Exercise | A | 0.62 | 2,100,000 | 1,302,000 | 4,200,000 | |
Feb 03 2010 | FCSC | Fibrocell Science, ... | Pernock David | Chief Executive Off ... | Option Exercise | A | 1.08 | 1,650,000 | 1,782,000 | 2,100,000 | |
Oct 02 2009 | FCSC | Fibrocell Science, ... | Pernock David | Director | Option Exercise | A | 0.75 | 450,000 | 337,500 | 450,000 |
Page: 1